ClinicalTrials.Veeva

Menu

An Observational Study to Assess the Effect of Calcineurin Inhibitors on Markers of Transplant Tolerance (OSCITT)

U

University Medical Center Goettingen

Status

Unknown

Conditions

Liver Transplantation

Study type

Observational

Funder types

Other

Identifiers

NCT01065584
OSCITT10

Details and patient eligibility

About

In experimental and clinical settings it has been shown that transplant tolerance is possible. It has been suggested that regulatory T cells play a beneficial role in the establishment of tolerance. Calcineurin inhibitors may inhibit development of regulatory T cells. However, the influence of calcineurin inhibitors on markers of transplant tolerance has not been studied in patients undergoing liver transplantation. Currently the investigators conduct a study to evaluate the safety and efficacy of a calcineurin inhibitor free immunosuppression in patients undergoing liver transplantation. In this study measurements of immune function and CD4+CD25high-Foxp3+-Il2/CD8+ status will also be performed. In parallel these measurements should be compared to a group of patients undergoing standard immunosuppression including calcineurin inhibitors.

Enrollment

58 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients undergoing primary liver transplantation
  • Patients of age 18 years and older
  • Female patients of childbearing potential willing to perform a highly effective contraception during the study and 12 weeks after conclusion of study participation

Exclusion criteria

  • Multiple organ graft recipients
  • Patients receiving ABO incompatible grafts
  • Patients with positive cross match
  • Pregnancy
  • Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule
  • Patients under guardianship (e.g. individuals who are not able to freely give their informed consent)

Trial design

58 participants in 2 patient groups

Standard immunosuppression
Description:
Patients receiving standard immunosuppression after liver transplantation including calcineurininhibitors
Immunosuppression without calcineurininhibitors
Description:
Patients receiving immunosuppression after liver transplantation not based on calcineurininhibitors

Trial contacts and locations

1

Loading...

Central trial contact

Aiman Obed, Prof. Dr.; Armin D Goralczyk, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems